Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Apr 02, 2017 6:29am
386 Views
Post# 26064278

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:one of the cool things I heard on the call today was

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:one of the cool things I heard on the call today wasI got mixed up with my fingers:-). The window for Pg BLA approval is Mid-June and early October.


Corrected post
Great info, Gobbs. Given that PLI started the rolling BLA submission in December and will complete this coming Wednesday, it is likely that FDA will grant the BLA sometime between mid June and early October (the 6 month window). I am confident that PLI will get priority review given that Pg has orphan drug status.

Pierre said that it is likely that the FDA will inspect their facilities in May. This opens the possibility for approval earlier than later (i.e. June/July). The big unknown is whether PLI will get a pediatric voucher at the time the BLA is granted? PLI certainly is in the running for a voucher. If PLI gets it, the Company will have a clear cash  runway until big revenues start flowing in 2018 from the commercialisation of Pg and IVIG.

In the interim, I also believe that the Company will deliver on a couple more regional deals. There is also the possibility of a massive partnership on IPF.

The next 6 months are going to be packed full of developments as both the PPPS and SMT platforms start delivering monetary results! I figure the next regional 4050 deal will send the shorts scurrying to the sidelines. It will be nice to have a short squeeze in the lead up to the AGM:-)
Bullboard Posts